Abstract
Literature data reporting SARS-CoV-2 infection in multiple sclerosis (MS) patients recently treated with immunodepleting agents as cladribine and alemtuzumab are very limited. The relationship between iatrogenic immunodeficiency and risk related to SARS-CoV-2 infection and its severe complications is still not clear. Cautiously, the start of immunosuppressant drugs as alemtuzumab and cladribine during the current COVID-19 pandemic is not recommended unless treatment benefits significantly outweigh potential risks. We report the case of a 30-year-old female MS patient infected by SARS-CoV-2 virus 4 months after alemtuzumab II cycle, while she was still leukopenic and lymphopenic. She had no complications and also presented milder COVID-related signs and symptoms as compared to her coinfected relatives (father, mother and her partner). Anti-S1 and S2 SARS-CoV-2 antibodies, tested 1 month and a half after the infection, resulted positive. We review all cases reported in literature of SARS-CoV-2 infection in MS patients treated with alemtuzumab. None of them had complications or severe disease.
Keywords: Alemtuzumab; Cladribine; Coronavirus; Immunodepleting agents; Multiple sclerosis; SARS-CoV-2.
【저자키워드】 SARS-CoV-2, coronavirus, multiple sclerosis, Cladribine, Alemtuzumab, Immunodepleting agents, 【초록키워드】 Treatment, SARS-CoV-2, SARS-COV-2 infection, COVID-19 pandemic, Infection, immunodeficiency, risk, SARS-CoV-2 virus, Symptom, drug, SARS-CoV-2 antibodies, female, Patient, Complication, literature, Anti-S1, mother, severe disease, positive, Multiple, benefit, tested, significantly, reported, treated, had no, severe complication, iatrogenic, lymphopenic, patients treated, 【제목키워드】 SARS-COV-2 infection, Case report, disease symptom,